Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RETSEVMO 40 mg CAPSULAS DURAS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RETSEVMO 40 mg CAPSULAS DURAS

Approved

STANDARD

RETSEVMO 40 mg CAPSULAS DURAS

Eli Lilly Nederland B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 4, 2021
Approval ID: 6fdabe506626a030
Company: Eli Lilly Nederland B.V.
Type: Standard

Approval Details

Approval Id: 6fdabe506626a030
Drug Cima Aemps Name: RETSEVMO 40 mg CAPSULAS DURAS
Register Number: 1201527001
Holder Company Name: Eli Lilly Nederland B.V.
Marketing Company Name: Lilly S.A.
Holder Company Detail Path: /organization/eli-lilly-nederland-bv
Marketing Company Detail Path: /organization/lilly-sa
Authorization Date: 2021-03-04
Dosage Form: CÁPSULA DURA
Dose: 40 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Eli Lilly Nederland B.V.
Company Detail Path: /organization/eli-lilly-nederland-bv

Company Information

Pharmaceutical Company Name: Eli Lilly Nederland BV
Country Name: Netherlands
Website: http://www.lilly.com/nl

Active Ingredients

SELPERCATINIB

40 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 4, 2021

Approval ID

6fdabe506626a030

Type

Standard

Back to CIMA-AEMPS Approvals